Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oliver & Co who wrote (3775)	2/8/1998 10:10:00 PM
From: Henry Niman	of 6136

Actually, I was giving the board my opinion. I'm sure that short term, the benefits of PIs are fairly clear. However, I suspect that the fat deposits are signaling more than a cosmetic peculiarity. My background is molecular (Ph.D. in Biochemistry), so when I read about gross physiological changes associated with relatively short term use of a new medication, I certainly do not characterize such observations as "insignificant". Since its rather widespread and associated with several forms of the same class of drugs, I would put such observations into the "highly significant" category.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next